The Sydney Brachytherapy Group is a tertiary referral clinic and a certified, licenced and accredited nuclear medicine medical facility at the interventional suites of the North Shore Medical Group. It offers multi-specialist, multidisciplinary healthcare and is a specialist treatment provider of Rhenium-SCT® (skin cancer therapy) for Non-Melanoma Skin Cancers.
SBG has specialist medical practitioners onsite and works with accredited visiting medical officers, including nuclear physicians, dermatologists, plastic surgeons, skin cancer surgeons and oncologists, to provide advanced beta-radiation brachytherapy for patients suffering from Basal Cell (BCCs), Squamous Cell Carcinomas (SCCs), Erythroplasia of Queyrat and Bowen’s disease.
Specialist Treatment Centre
Onsite Medical Practitioners
What is Brachytherapy?
Brachytherapy is a form of radiation therapy. It has become the modality of choice for certain cancer localisations because it minimises the risk to surrounding healthy tissues.
Rhenium-SCT® (skin cancer therapy) is brachytherapy for Non-Melanoma Skin Cancers (NMSC). An advance radionuclide therapy technology, it offers a non-invasive, predominantly single-session1-3* treatment with improved cosmetic outcomes.1,4
*Complete tumour regression in 98.5% of lesions treated.
†No disfiguring scarring.
Rhenium-SCT® uses a non-invasive paste containing ß-emitting particles, applied directly onto a skin lesion, which targets cancer cells without the need for surgery. This treatment offers skin cancer patients a non-surgical alternative.
ß-particles can only penetrate the human tissue up to 2-3 mm deep. It is ideal in treating superficial skin cancers without affecting other parts of the body. This treatment is specifically for patients suffering from Basal Cell Carcinomas (BCCs), Squamous Cell Carcinomas (SCCs), Erythroplasia of Queyrat and Bowen’s disease.
Primary or secondary referrals are required from all patients from either a general practitioner (GP), specialist skin cancer surgeons or specialist dermatologists.
What do I need to know about rhenium skin cancer therapy?
Rhenium skin cancer therapy is a specialised state-of-the-art brachytherapy utilising the radioisotope Rhenium-188, a beta-emitter which in this case is used for the treatment of basal and squamous cell carcinomas of the skin.
This epidermal radioisotope therapy is based on the local direct cell-killing effect of the beta-radiation, which triggers both the local death of cells and local reactions of the immune system of the body to repair itself.